Vistin Pharma ASA 2024 SR
The report highlights Vistin Pharma's commitment to sustainable pharmaceutical production, specifically for Metformin API, utilizing 100% renewable hydropower. The company achieved a 90% recycling grade at its plant and reduced water consumption by 80% through innovative recycling initiatives. Vistin Pharma has set an ambitious target to be carbon neutral in Scope 1 and Scope 2 emissions by 2030. Furthermore, the report details significant investments in technology to reduce volatile organic compound (VOC) emissions by 95% and ensure minimal environmental impact on local fjords.
Company: Vistin Pharma ASA
Sector: Health Care
Country: Norway
Year: 2024
Type: SR
Pages: 10
Vistin Pharma ASA
Sustainability Report
The report highlights Vistin Pharma's commitment to sustainable pharmaceutical production, specifically for Metformin API, utilizing 100% renewable hydropower. The company achieved a 90% recycling grade at its plant and reduced water consumption by 80% through innovative recycling initiatives. Vistin Pharma has set an ambitious target to be carbon neutral in Scope 1 and Scope 2 emissions by 2030. Furthermore, the report details significant investments in technology to reduce volatile organic compound (VOC) emissions by 95% and ensure minimal environmental impact on local fjords.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Water Consumption
Net Zero Target
Employees